Aardvark Therapeutics AARD
NASDAQ AARD
$4.35 +0.45 (+11.54%)
As of: Oct 21, 2026 · 11:29 AM EDT

Aardvark Therapeutics (AARD) EBITDA (2024 - 2026)

Updated

Aardvark Therapeutics (AARD) recorded EBITDA of -$15.07 million in Q2 2026, compared with -$15.84 million a year earlier.

Analysis

Aardvark Therapeutics (AARD) EBITDA (2024 - 2026) Analysis & Trends

On a TTM basis, Aardvark Therapeutics' EBITDA came in at -$73.91 million as of Jun 30, 2026; for FY2025, it came in at -$62.69 million.

  • Across earlier years, EBITDA came in at -$22.77 million in FY2024.
  • The Q2 2026 figure is the highest quarterly EBITDA since Q1 2025.
  • Per Business Quant, the preceding three quarters came in at -$22.45 million (Q1 2026), -$18.69 million (Q4 2025) and -$17.69 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Eli Lilly 1,130.87 Bn 1,099.45 Bn 19.71 Bn 12.29 Bn
2 Johnson & Johnson 614.49 Bn 533.02 Bn 17.26 Bn 9.10 Bn
3 AbbVie 502.45 Bn 475.56 Bn 12.70 Bn 8.33 Bn
4 Merck 368.35 Bn 322.73 Bn 12.21 Bn 999.00 Mn
5 Novartis Ag 298.42 Bn 262.41 Bn 11.24 Bn -
6 Astrazeneca 261.95 Bn 235.64 Bn 12.86 Bn 5.09 Bn
7 Amgen 235.96 Bn 191.36 Bn 7.24 Bn 4.63 Bn
8 Gilead Sciences 191.17 Bn 165.37 Bn 6.22 Bn -9.70 Bn
9 Pfizer 169.80 Bn 116.45 Bn 10.94 Bn 5.89 Bn
10 Aardvark Therapeutics 95.03 Mn 21.13 Mn - -15.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -15.07 Mn
Mar 31, 2026 -22.45 Mn
Dec 31, 2025 -18.69 Mn
Sep 30, 2025 -17.69 Mn
Jun 30, 2025 -15.84 Mn
Mar 31, 2025 -10.47 Mn
Dec 31, 2024 -9.44 Mn
Sep 30, 2024 -5.08 Mn
Jun 30, 2024 -6.08 Mn
Mar 31, 2024 -2.17 Mn
API Access

Aardvark Therapeutics EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda&ticker=AARD&period=max&api_key=YOUR_API_KEY